



The TIMI Trials

TIMI IIIB

OBJECTIVE: To assess the early effects of rtPA vs. placebo and the clinical efficacy of an early invasive vs. conservative strategy in a 2x2 factorial design among patients with unstable angina and non-Q-wave myocardial infarction.

1. **TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial. *Circulation* 1994;89:1545-56.**
2. Becker RC, Bovill EG, Corrao JM, Ball SP, Ault K, Mann K, Tracy RP. Platelet activation determined by flow cytometry persists despite antithrombotic therapy in patients with unstable angina and non-Q wave myocardial infarction. *J Thromb Thrombolysis* 1994;1:95-100.
3. Becker RC, Tracy RP, Bovill EG, Corrao JM, Baker S, Ball SP, Mann K. Surface 12-lead electrocardiogram findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest. *J Thromb Thrombolysis* 1994;1:101-7.
4. Becker RC, Tracy RP, Bovill EG, Mann KG, Ault K, TIMI III Thrombolysis and Anticoagulation Group. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. *Coronary Artery Disease* 1994;5:339-345.
5. Anderson HV, Williams DO, Powers E, Cannon CP, Stone P, Sharaf B, Thompson B, Schactman M, Willerson JT, for the TIMI-IIIB Investigators. Coronary thrombus seen on early angiography in unstable angina/non Q wave MI: TIMI-IIIB results. *Circulation* 1994;90[Pt. 2]:I-664.
6. Becker R, Tracy R, Thompson B, Mann K, Bovill E, for the TIMI IIIB Investigators. Anticoagulation profile in heparinized patients with unstable angina and non-Q wave myocardial infarction experiencing clinical events. *Circulation* 1994;90 [Pt 2]:I-664.
7. Buller CE, Fung AY, Thompson CR, Ricci DR, Thompson B, Schactman M, Williams DO. Does pre-treatment with tPA improve safety of coronary angioplasty in acute coronary syndromes? Results from TIMI IIIB. *Circulation* 1994;90[Pt. 2]:I-22.
8. Becker R, Tracy R, Bovill E, Thompson B, Randall A, Cannon C, Braunwald E. Should aPTT assays be standardized in multicenter clinical trials designed to investigate the benefits of heparin? *J Am Coll Cardiol* 1994;57A.
9. Hadjis T, Lam JYT, Theroux P, Sampalis J, Nasmith J, Randall A, Bovill E, Tracy R, and the TIMI-3 Study Group. Interaction between heparin and nitroglycerin: an ancillary TIMI-III Study. *Circulation* 1994;90[Pt. 2]:I-374.
10. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, Thompson B, Willerson JT, Braunwald E. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. *J Am Coll Cardiol* 1995;26:1643-50.
11. Cannon CP, Thompson B, McCabe CH, Mueller HS, Kirshenbaum JM, Herson S, Nasmith JB, Chaitman BR, Braunwald E. Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials. *Am J Cardiol* 1995;75:977-81.
12. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. *N Engl J Med* 1996;335:1342-9.
13. Becker RC, Cannon CP, Bovill EG, Tracy RP, Thompson B, Knatterud GL, Randall A, Braunwald E. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial). *Am J Cardiol* 1996;78:142-7.

14. Becker RC, Cannon CP, Tracy RP, Thompson B, Bovill EG, Desvigne-Nickens P, Randall AM, Knatterud G, Braunwald E for the Thrombolysis in Myocardial Ischemia III B Investigators. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardial infarction. *Am Heart J* 1996;131:421-33.
15. Williams D, Braunwald E, Thompson B, Sharaf B, Buller C, Knatterud G. Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction. Observations from the TIMI IIIB trial. *Circulation* 1996;94:2749-2755.
16. Hochman JS, McCabe CH, Stone PH, Becker RC, Cannon CP, DeFeo-Fraulini T, Thompson B, Steingart R, Knatterud G, Braunwald E, for the TIMI Investigators. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. *J Am Coll Cardiol* 1997;30:141-8.
17. Jain D, Thompson B, Wackers F, Zaret B, TIMI-IIIB Investigators. Relevance of increased lung thallium uptake on stress imaging in patients with unstable angina and non-Q wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI)-IIIB study. *J Am Coll Cardiol* 1997;30:421-429.
18. Becker RC, Cannon CP, Tracy RP, Bovill E, Spencer F, Burns M, Ball SP, for the TIMI III Investigators. Fibrinogen, an acute phase protein is not a marker of thrombin- or platelet-mediated prothrombotic potential in unstable angina. *J Am Coll Cardiol* 1997;29 (Suppl. A):411A.
19. Fung AY, Gawad Y, Thompson CR, Jackowski G, Leitmann R, Antman EM, Tanasijevic MJ, Canner J, Thompson B, Braunwald E. The prognostic value of cardiac myosin light chains in acute ischemic syndromes-results from TIMI 3B. *J Am Coll Cardiol* 1998;31 (Suppl. A):380A.
20. Stone PH, Thompson B, Zaret BL, Chaitman B, Gibson RS, Schweiger MJ, Steingart R, Kirshenbaum J, Thompson C, Fung A, McCabe CH, Knatterud GL, Braunwald E. Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction. A TIMI-IIIB database study. *Eur Heart J* 1999;20:1084-93.
21. Tanasijevic MJ, Cannon CP, Antman EM. The role of cardiac troponin-I (cTnI) in risk stratification of patients with unstable coronary artery disease. *Clin Cardiol* 1999;22:13-6.
22. Solomon DH, Stone PH, Glynn RJ, Ganz DA, Gibson CM, Tracy R, Avorn J. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. *J Am Coll Cardiol* 2001;38:969-76.
23. Solomon DH, Ganz DA, Avorn J, Glynn RJ, Knight EL, Gibson CM, Stone PH. Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. *J Clin Epidemiol* 2002;55:121-8.
24. Desai AS, Solomon DH, Stone PH, Cannon CP, Avorn J. Economic consequences of routine coronary angiography in low-risk patients with unstable angina. *J Am Coll Cardiol* 2002;39 (Suppl A):447A.
25. Sabatine MS, Morrow DA, Giugliano RP, Murphy SA, Demopoulos LA, DiBattiste PM, Weintraub WS, McCabe CH, Antman EM, Cannon CP, Braunwald E. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: A comparison of the Thrombolysis in Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. *Circulation* 2004;109:874-880.